IL6 and COVID-19: The data that advocate a beneficial role of ACEI and ARAII are based on the existence of lower levels of cytokines, decreasing inflammatory levels and IL6 expression in patients with severe COVID-19, and lower associated mortality data [48,49,50], as well as a possible protective factors for severe cases [51,52].